Trade Unlisted is not regulated by the Securities and Exchange Board of India (SEBI). Investments in unlisted securities involve significant risk, including the risk of complete loss of capital. The filing of a Draft Red Herring Prospectus (DRHP) does not guarantee that an Initial Public Offering (IPO) will occur. Unlisted securities are inherently illiquid, price discovery may be limited, and exit opportunities may not materialize.
Trade Unlisted provides news, insights, and general market information for informational and educational purposes only. The content should not be construed as financial, investment, legal, or tax advice. Trade Unlisted does not act as a broker, investment advisor, fiduciary, or intermediary, and does not endorse, recommend, solicit, or validate any investment opportunity. Users are solely responsible for conducting their own independent due diligence before making any financial or investment decisions.
All information is derived from publicly available sources and market observations. While reasonable care is taken in preparing content, Trade Unlisted makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of the information provided. Users should independently verify all information prior to relying on it.
Maverick Simulation Solutions Ltd – Building a Scalable MedTech Story
1. The Opportunity They Are Tapping
Medical education is undergoing a structural shift from traditional learning to simulation-based training
Increasing need for safe, repeatable, and technology-driven training environments
Strong push from:
- Government initiatives
- Digitization in healthcare
- Import substitution (Make-in-India)
Maverick is positioned at the intersection of healthcare, technology, and education
2. What Maverick Does
A Delhi-based medtech company building clinical and surgical simulation systems
Enables training without real patients or cadavers
Offers an integrated platform:
- Hardware (simulators)
- Software (AI/VR-based training)
- End-to-end simulation infrastructure
Positioned as a full-stack simulation solutions provider
3. Early Positioning Advantage
Among the only Indian players with end-to-end capabilities
Provides after-sales support, which is a key gap in this segment
Early mover in high-fidelity simulators, creating:
- Strong client stickiness
- High switching costs
Active participation in government ecosystem:
- 20+ products listed on GeM
- Regular tender participation
4. Product Ecosystem – Built for Scale
Portfolio spans across the entire value chain:
- High-fidelity simulators (advanced, high-value)
- Low-fidelity simulators (volume-driven training tools)
- Surgical simulators (specialized use cases)
- Digital immersive simulators (AI/VR/AR-based)
This allows:
- Presence across all price points
- Wider customer adoption
- Potential for cross-selling and recurring demand
5. Technology as the Core Differentiator
Deep integration of:
- Artificial Intelligence
- Virtual Reality and Augmented Reality
Strong IP base:
- 8 patents granted
- 15+ under process
Backed by a technocrat-led management team, focused on innovation and scale
6. From Early Stage to Rapid Scale-Up
Business has moved from low base to rapid scale within a short period
Financial progression:
- FY24: ₹60 Cr revenue | ₹20 Cr PAT
- FY25: ₹118 Cr revenue | ₹40 Cr PAT
- FY26E: ₹200 Cr revenue | ₹75 Cr PAT
Margins remain strong at 33–38% PAT, indicating:
- High operating leverage
- Scalable economics
Revenue growth and profitability have expanded simultaneously, not at the cost of margins
7. Operating Leverage Kicking In
Sharp improvement in margins:
- FY24: Low margins (~6–10%)
- FY25: Significant jump (30%+)
Indicates transition from:
- Investment phase → monetization phase
8. Execution on Ground
Strong operational footprint:
- 100+ installations
- 200+ customers
- 60+ top institutions
Training impact:
- Over 500,000 trainees trained
R&D investment of ~₹50 Cr shows long-term commitment to innovation
9. Credibility Through Early Wins
Delivered multiple “first-of-its-kind” projects:
- Advanced patient simulators with ventilation systems
- Installations at leading institutions like AIIMS Bhopal
- Simulation labs in emerging segments like AYUSH
Builds credibility in a trust-driven institutional market
10. Growth is Not Just Domestic
Clear intent to become a global medtech player
Key initiatives:
- Entry into the US market (largest global demand pool)
- Exploring acquisition of an international player
- Building global distribution and reach
11. Strategic Direction
Focus areas going forward:
- Expansion of AI/VR/AR-based solutions
- Sustainability-led manufacturing
- Complete import substitution through in-house production
Objective is to build a self-reliant, globally competitive platform
12. Shareholding and Investor Interest
- Promoters hold ~82%, indicating strong control
- Manish Khurana and Sumit Gupta hold ~5% combined
- Increasing participation from institutional and HNI investors
13. Why the Story Looks Attractive
- Operates in a niche, underpenetrated market
- Combines deep tech + healthcare + education
- Strong margin profile with visible scalability
- Beneficiary of long-term structural and policy tailwinds
14. What Needs Close Monitoring
Sustainability of high margins as scale increases
Dependence on government and institutional orders
Execution risks in:
- Global expansion
- Acquisition strategy
Cash flow conversion and working capital discipline
15. The Larger Picture
Maverick is transitioning from:
- A domestic niche player
- To a globally scalable, IP-led medtech platform
The company sits in a space where:
- Demand is structural
- Competition is limited (especially domestically)
Conclusion
Maverick represents a high-growth, high-margin, technology-driven opportunity in medtech
The business model, if executed well, has the potential to scale significantly
However, the next phase of the story will depend on:
- Execution consistency
- Cash flow quality
- Success in global expansion
Comments